Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B

The Italian company Angelini Pharma said Thursday it would buy the rare-disease focused Catalyst Pharmaceuticals for roughly $4.1 billion in cash. 

The deal values Florida-based Catalyst at $31.50 a share, a 28% premium to the 30-day period before April 22, when it became publicly known that a deal was in the works. 

Buying Catalyst, which sells three approved medicines, will give Angelini a foothold in the U.S. market. It also builds on its work in neurology. 

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In